Registry of Lobbyists

Registration - In-house Corporation

Apotex Inc. / Jeff Watson, President

Registration Information

In-house Corporation name: Apotex Inc.
Previous in-house corporation names
Responsible Officer Name: Jeff Watson, President 
Responsible Officer Change History
Initial registration start date: 1996-06-26
Registration status: Inactive
Registration Number: 938533-452

Associated Communications

Total Number of Communication Reports: 39

Monthly communication reports in the last 6 months: 0

Version 1 of 29 (1996-06-26 to 1997-03-12)

Version 1 of 29 (1996-06-26 to 1997-03-12) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Lobbyist and Corporation

Corporation: APOTEX INC.
150 SIGNET DRIVE
WESTON, ON  M9L 1T9
Canada
Telephone number: 416-749-9300
Fax number: 416-749-9578  
Responsible officer name and position during the period of this registration: JACK KAY, PRESIDENT & COO  
Description of activities: APOTEX IS A CANADIAN-OWNED PHARMACEUTICAL COMPANY WHICH RESEARCHES DEVELOPS, MANUFACTURES AND DISTRIBUTES 150 MEDICINES TO THE HEALTH CARE SYSTEM AND EXPORTS THESE TO 110 COUNTRIES. APOTEX'S 1996 R&D BUDGET WAS $55.9 MILLION - POSITIONING IT IN THE TOP 18 COMPANIES FOR ALL INDUSTRIALSECTORS.
 
Parent: The corporation is not a subsidiary of any other parent corporations.
Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Canadian Heritage (PCH), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Justice Canada (JC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Revenue Canada (RC)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Government Procurement, Health, Industry, Intellectual Property, International Trade, Justice and Law Enforcement, Science and Technology, Taxation and Finance
 
Subject Matter: Particulars: KEY SUBJECT MATTERS: INTELLECTUAL PROPERTY PATENET ACT/1997 REVIEW/ PATENT REGULATION DRUG REGULATIONS(APPROVAL REVIEW) TRADE/EXPORTS TAX ACT/REVENUE CANADA;CHARITABLE FOUNDATION GOVERNMENT PROCUREMENT MRC/SCIENCE & TECHNOLOGY HEALTH CANADA - HEALTH ACT COMPETITION BUREAU




Date Modified: